CLINUVEL expands Singapore RD&I Centre to pioneer next-generation peptide therapies
EXECUTIVE SUMMARY VALLAURIX Research, Development & Innovation Centre to expand its existing facilities and capabilities core focus on accelerating development of liquid long-acting drug delivery platforms existing RD&I teams will advance late-stage development programs without disruption strategic investment supported by the Singaporean Economic Development Board (EDB) five-year funded plan MELBOURNE, Australia and SINGAPORE, Dec. 07, 2025 (GLOBE NEWSWIRE) -- CLINUVEL PHARMACEUTICALS LTD today announced a significant expansion of its VALLAURIX Research, Development and Innovation (RD&I) Centre in Singapore. This strategic five-year investment solidifies the site's transition into a global hub for developing advanced, long-acting peptide formulations.